Literature DB >> 26312213

Treatment of localized prostate cancer in elderly patients.

Mohammed Haseebuddin1, Marc C Smaldone1.   

Abstract

Prostate cancer is a disease of the elderly. According to National Cancer Institute, more than 56.7% of incident cases are diagnosed and more than 90% of cancer specific deaths occur in men greater than 65 years of age. Despite equivalent oncologic outcomes with treatment, primary local therapy is often deferred in elderly men with high-risk prostate cancer, in part due to concerns that post surgery quality of life (QOL) functional outcomes compare poorly to younger men. Our aim in this editorial is to discuss the functional and oncological outcomes in management of elderly with localized prostate cancer.

Entities:  

Keywords:  Prostate cancer; elderly patients; local therapy

Year:  2015        PMID: 26312213      PMCID: PMC4523629          DOI: 10.3978/j.issn.2227-684X.2015.06.09

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  29 in total

1.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

2.  The effect of age on functional outcomes after radical prostatectomy.

Authors:  Philipp Mandel; Markus Graefen; Uwe Michl; Hartwig Huland; Derya Tilki
Journal:  Urol Oncol       Date:  2015-03-24       Impact factor: 3.498

3.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Authors:  Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson
Journal:  Lancet Oncol       Date:  2011-08-05       Impact factor: 41.316

4.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.

Authors:  W J Catalona; G F Carvalhal; D E Mager; D S Smith
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

7.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  D P Lubeck; M S Litwin; J M Henning; D M Stier; P Mazonson; R Fisk; P R Carroll
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

8.  Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.

Authors:  Lindsay A Hampson; Janet E Cowan; Shoujun Zhao; Peter R Carroll; Matthew R Cooperberg
Journal:  Eur Urol       Date:  2015-02-02       Impact factor: 20.096

9.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.